Clene Inc. Form 8-K Summary
Business context and reporting period
Clene Inc. filed a Form 8-K dated February 1, 2022, reporting executive leadership changes and related employment arrangements. The filing does not present quarterly or annual financial results and does not specify a financial reporting period.
Key financial and compensation information
- Morgan Brown was appointed Chief Financial Officer, principal financial officer, and principal accounting officer, effective February 1, 2022.
- Mr. Brown’s annual base salary is $375,000, with an annual bonus target of 40% of base salary, subject to milestones determined by the Board and Compensation Committee.
- President and Chief Executive Officer Robert Etherington entered into a revised employment agreement providing for a $560,000 annual base salary and a bonus target of 50% of base salary.
- Chief Medical Officer Robert Glanzman’s amended agreement provides for a $410,000 annual base salary and a bonus target of 40% of base salary.
- Former CFO Tae Heum (Ted) Jeong will receive $20,000 for consulting services through December 31, 2022 and an $80,000 bonus for services rendered in 2021.
- The filing provides no revenue, profit, cash flow, margin, debt, cash balance, liquidity, or operating expense figures.
Material changes versus the prior comparable period
- Morgan Brown replaced Dr. Jeong as CFO effective February 1, 2022.
- Dr. Jeong resigned to pursue other opportunities. The filing states that his departure was not related to any disagreement concerning financial reporting or accounting policies, procedures, estimates, or judgments.
- Dr. Jeong will remain a consultant through December 31, 2022. Certain outstanding and unvested equity awards will vest at the end of, or continue vesting during, the consulting period.
- The Company terminated Mr. Etherington’s prior executive officer letter agreement and replaced it with a revised executive employment agreement. Dr. Glanzman’s employment agreement was also amended.
Guidance, outlook, risks, contingencies, and unusual items
- No financial guidance or operating outlook was provided.
- Employment agreements include severance, bonus, equity-acceleration, benefits, and change-in-control provisions. Specific benefits vary depending on the termination circumstances and compliance with release requirements.
- If Mr. Brown is terminated without cause or resigns for good reason, he may receive one times base salary, a bonus based on the actual bonus that would have been earned, accelerated vesting of outstanding unvested equity awards, and certain COBRA reimbursements. Qualifying termination events near or following a change in control may increase the salary and target-bonus component to two times.
- The filing states that certain information in employment-agreement exhibits was redacted under Item 601(a)(6) of Regulation S-K.
Important facts for investors to verify
- Review the full employment agreements and separation agreement filed as Exhibits 10.1 through 10.5 for complete severance, equity, bonus, and change-in-control terms.
- Assess the potential compensation and equity-related expense from the new executive agreements and Dr. Jeong’s consulting and vesting arrangements.
- Confirm Mr. Brown’s responsibilities as both principal financial officer and principal accounting officer.
- Review subsequent filings for any additional leadership changes, financial results, liquidity updates, or disclosures regarding the impact of these arrangements.